Fig. 5

K3016 CA: I201V mutant is partially resistant and compound-dependent. HEK-293T cells were transfected with the HIV-1 subtype C K3016 WT and K3016 CA: I201V mutant and treated with 100 nM and 500 nM of the BVM-analog CV-8613 or with DMSO only. a The CA-SP1 accumulation assay was performed. Gel images shown here are representative of three independent experiments. Quantification of % CA-SP1 relative to total CA + CA-SP1 is presented in the graphs. b The viruses produced by BVM-analog-treated HEK-293T cells were quantified, and TZM-bl cells were infected with these MI-treated HIV-1 viruses for 48 h. The cells were lysed and assayed for luciferase activity. Quantitative data for levels of infectivity relative to the DMSO control-treated sample is shown. Error bars indicate standard deviations from three independent experiments. The asterisks indicate significant differences (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001) and ns indicates not significant. c The HUT-R5 T-cells were transfected with the HIV-1 Subtype C molecular clone K3016 WT and K3016 CA: I201V mutant. Transfected cells were propagated in the presence of 100 nM and 500 nM of the BVM-analog CV-8613 or with DMSO only. Virus replication was monitored by quantifying HIV-1 p24 concentration in the culture supernatant, and the replication profile was represented as a graph